{"id":3285,"date":"2019-03-05T15:43:43","date_gmt":"2019-03-05T15:43:43","guid":{"rendered":"http:\/\/blogs.sld.cu\/inorbib\/?p=3285"},"modified":"2019-03-05T15:43:43","modified_gmt":"2019-03-05T15:43:43","slug":"alk-versus-egfr-positive-nsclc-ct-imaging-and-clinical-characteristics","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/inorbib\/2019\/03\/05\/alk-versus-egfr-positive-nsclc-ct-imaging-and-clinical-characteristics\/","title":{"rendered":"ALK\u2013 Versus EGFR-positive NSCLC: CT Imaging and Clinical Characteristics"},"content":{"rendered":"<h5 class=\"post-heading heading\">In a retrospective study of Asian patients with non-small cell lungcancer (NSCLC), there were differences in computed tomography (CT) findings depending on if a disease was characterized by an <em>ALK\u00a0<\/em>gene rearrangement or an activating <em>EGFR\u00a0<\/em>mutation.<\/h5>\n<h5>Upfront molecular testing for <em>ALK\u00a0<\/em>and <em>EGFR<\/em> alterations is recommended for all patients with a diagnosis of advanced NSCLC characterized by a non squamous histology. However, clinical features and imaging-related characteristics associated with particular molecular forms of advanced NSCLC may provide useful information related to raising clinical suspicion for a particular molecular subtype of the disease.<\/h5>\n<h5>In particular, <em>ALK <\/em>and <em>EGFR<\/em> alterations are generally considered to be mutually exclusive, and previous reports on imaging results related to <em>ALK<\/em>-positive NSCLC have been conflicting.<\/h5>\n<p>Related Articles.<\/p>\n<ul class=\"list\">\n<li class=\"item\"><a class=\"link\" href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/lung-cancer\/overall-survival-in-patients-with-stage-iv-alk-positive-non-small-cell-lung-cancer-treated-with-crizotinib\/\">Overall Survival in Patients With Stage IV <i>ALK<\/i>-Positive Non-Small Cell Lung Cancer Treated With Crizotinib.<\/a><\/li>\n<li class=\"item\"><a class=\"link\" href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/lung-cancer\/lung-cancer-news\/genomic-profiling-using-guardant-360-cell-free-dna-based-assay-vs-tumor-based-genotyping-assays-in-advanced-nsclc\/\">Genomic Profiling Using Guardant 360 Cell-Free DNA-Based Assay vs Tumor-Based Genotyping Assays in Advanced NSCLC<\/a>.<\/li>\n<\/ul>\n<p>This study included 201 patients with NSCLC characterized by the type of mutation found; patients were classified according to the following molecular subgroups: <em>ALK <\/em>(21 patients), <em>EGFR<\/em> (124 patients), and non-<em>ALK\/EGFR<\/em>(56 patients). Compared with patients in the <em>EGFR<\/em> subgroup, CT findings for patients in the <em>ALK<\/em> subgroup were more likely to be characterized by a large mass (<em>P <\/em>=.0155), a solid mass (<em>P <\/em>=.0048), no air bronchogram (<em>P <\/em>=.0148), a central location (<em>P <\/em>=.0322), and lymphadenopathy (<em>P <\/em>=.0353).<\/p>\n<p>Compared with the non-<em>ALK\/EGFR<\/em> subgroup, patients in the <em>ALK<\/em> subgroup were less likely to have coexisting emphysema (<em>P <\/em>=.0135),more likely to be female (<em>P <\/em>=.0043),and a light or never-smoker (<em>P <\/em>=.0039).In addition, patients with disease characterized by an <em>ALK<\/em> alteration were more likely to be younger compared with those in the <em>EGFR<\/em> subgroup (<em>P <\/em>=.0156). Following multivariate analysis including all CT and clinical variables, air bronchogram, emphysema,and a central location were independently associated with <em>ALK<\/em> status.<\/p>\n<p>Limitations of this study, as noted by the study authors, included its retrospective design, and the small number of patients in the <em>ALK<\/em> subgroup.<\/p>\n<h6><strong>Reference<\/strong><\/h6>\n<ol>\n<li>\n<h6><em>Mori M, Hayashi H, Fukuda M, et al. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30811109\">Clinical and computed tomographycharacteristics of non-small cell lungcancer with ALK generearrangement: Comparison with EGFR mutation and ALK\/EGFR-negative lung cancer<\/a> [published online February 27, 2019]. Thorac Cancer. doi:10.1111\/1759-7714.13017<\/em><\/h6>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>In a retrospective study of Asian patients with non-small cell lungcancer (NSCLC), there were differences in computed tomography (CT) findings depending on if a disease was characterized by an ALK\u00a0gene rearrangement or an activating EGFR\u00a0mutation. Upfront molecular testing for ALK\u00a0and EGFR alterations is recommended for all patients with a diagnosis of advanced NSCLC characterized by [&hellip;]<\/p>\n","protected":false},"author":176,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3285"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/users\/176"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/comments?post=3285"}],"version-history":[{"count":1,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3285\/revisions"}],"predecessor-version":[{"id":3286,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3285\/revisions\/3286"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/media?parent=3285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/categories?post=3285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/tags?post=3285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}